Wisconsin Alumni Research Foundation Patent Portfolio Statistics

Wisconsin Alumni Research Foundation

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Wisconsin Alumni Research Foundation look like?

Total Applications: 4,032
Granted Patents: 2,900
Grant Index 81.35 %
Abandoned/Rejected Applications: 665 (18.65%)
In-Process Applications: 450
Average Grant Time: 3.16 Years
Average Office Actions: 1.92

Which Technology Area Wisconsin Alumni Research Foundation is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1632 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 146
Opap Parked GAU 122
1648 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 112
1636 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 93
1652 Fermentation, Microbiology, Isolated and Recombinant Proteins/Enzymes 87

How many patents are Wisconsin Alumni Research Foundation filing every year?

Year Total Applications
2022 0*
2021 107*
2020 127
2019 163
2018 189

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Wisconsin Alumni Research Foundation in USPTO?

Publication number: US20220025053A1
Application number: 17/495,893

Abstract:
As described herein, a method of inhibiting metastasis in cancer includes administering to a human subject diagnosed with a cancer of an organ of the peritoneal cavity a therapeutically effective amount of an inhibitor of CCR5 or P-selectin. Preferably the subject has a tumor positive for a ligand of P-selectin such as a CD24+ or PSGL-1+ tumor. Analysis of samples from HGSOC patients confirmed increased MIP-1β and P-selectin, suggesting that this novel multi-cellular mechanism can be targeted to slow or stop metastasis in cancers such as high-grade serous ovarian cancer, for example by using anti-CCR5 and P-selectin therapies developed for other indications.

Publication date: 2022-01-27
Applicant: Wisconsin Alumni Research Foundation
Inventors: Kay Kreeger Pamela


Publication number: US20220022498A1
Application number: 17/495,336

Abstract:
The disclosure provides for compositions and methods for the preservation of meat substitutes containing plant heme protein. In particular, small molecules that can fit in the unique heme pocket of plant heme proteins are provided to stabilize and preserve meat substitutes the products.

Publication date: 2022-01-27
Applicant: Wisconsin Alumni Research Foundation
Inventors: Hargrove Mark


Publication number: US20220023444A1
Application number: 17/494,457

Abstract:
Described herein are CRISPR/Cas9 constructs designed for the C-terminal truncation of human amyloid precursor protein (APP) as well as methods of making and using such a construct.

Publication date: 2022-01-27
Applicant: Wisconsin Alumni Research Foundation
Inventors: Jichao Sun


How are Wisconsin Alumni Research Foundation’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/495,893 Methods Of Inhibiting Metastasis In Cancer OPAP Central, Docket
17/495,336 Compositions And Methods Of Preserving Meat Substitutes 1791
17/494,457 Gene Editing-Based Method Of Attenuating The Beta-Amyloid Pathway OPAP Central, Docket
17/480,239 Phospholipid Ether Analogs For Imaging And Targeted Treatment Of Pediatric Solid Tumors OPAP Central, Docket
17/474,174 Unbiased Dna Methylation Markers Define An Extensive Field Defect In Histologically Normal Prostate Tissues Associated With Prostate Cancer: New Biomarkers For Men With Prostate Cancer Docketed New Case – Ready for Examination OPAP Central, Docket